Latest Breaking News On - Christopher peetz - Page 6 : comparemela.com

Analysts Anticipate Mirum Pharmaceuticals, Inc (NASDAQ:MIRM) Will Announce Earnings of $0 03 Per Share

Equities research analysts expect Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) to announce earnings of $0.03 per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Mirum Pharmaceuticals’ earnings, with estimates ranging from ($2.45) to $2.18. Mirum Pharmaceuticals posted earnings per share of ($1.43) in the same quarter […]

Foster cityUnited statesLos angelesNiall odonnelRaymond jamesRaymond james financial services advisors incGeode capital managementMirum pharmaceuticalsZacks investment researchMirum pharmaceuticals get ratingInvesco ltdLos angeles capital managementMirum pharmaceuticals incCitigroup incGet ratingMirum pharmaceutical

$0 03 EPS Expected for Mirum Pharmaceuticals, Inc (NASDAQ:MIRM) This Quarter

Analysts expect Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) to post $0.03 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Mirum Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($2.45) and the highest estimate coming in at $2.18. Mirum Pharmaceuticals posted earnings of […]

United statesNiall odonnelRaymond jamesSteward partners investment advisoryMirum pharmaceuticalsMirum pharmaceuticals company profile get ratingZacks investment researchCongress wealth managementAmerica corpCubist systematic strategiesMirum pharmaceuticals incCitigroup incGet ratingMirum pharmaceuticalPartners investment advisorySystematic strategies

Mirum Pharmaceuticals, Inc (NASDAQ:MIRM) Sees Significant Drop in Short Interest

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) was the recipient of a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 468,200 shares, a decline of 18.1% from the January 31st total of 571,900 shares. Based on an average daily trading volume, of 166,100 shares, […]

Foster cityUnited statesLos angelesNiall odonnelRaymond jamesRaymond james financial services advisors incGeode capital managementMirum pharmaceuticalsMirum pharmaceuticals company profile get ratingZacks investment researchInvesco ltdLos angeles capital managementMirum pharmaceuticals incCitigroup incGet ratingAngeles capital management

Strs Ohio Cuts Holdings in Mirum Pharmaceuticals, Inc (NASDAQ:MIRM)

Strs Ohio Cuts Holdings in Mirum Pharmaceuticals, Inc (NASDAQ:MIRM)
etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.

Thomson reuterNiall odonnelRaymond jamesIan clementsRobertw bairdMorgan stanleyMesirow financial investment management incMirum pharmaceuticalsSecurities exchange commissionZacks investment researchRenaissance technologiesQuarter for mirum pharmaceuticalsMirum pharmaceuticals incStrs ohioStreet corpMesirow financial investment management

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Daily Biotech Pulse: FDA Nod For Amphastar s Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Daily Biotech Pulse: FDA Nod For Amphastar s Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Hong kongKeith grossmanChristopher peetzWilliam liangNovo nordiskZai labVirios therapeuticsGilead sciences incAprea therapeutics incLiquidia corpZai lab licensed ovarian cancer drug eligibleZai lab ltdAlkermes plcBristol myers squibb coInhibikase therapeutics incEuropean medicines agency for ozempic